Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct;85(4):436-480.
doi: 10.1016/j.jinf.2022.06.011. Epub 2022 Jun 17.

COVID-19 "Rebound" associated with nirmatrelvir/ritonavir pre-hospital therapy

J M Coulson  1 , A Adams  2 , L A Gray  3 , A Evans  4
Affiliations

COVID-19 "Rebound" associated with nirmatrelvir/ritonavir pre-hospital therapy

J M Coulson et al. J Infect. 2022 Oct.
No abstract available

Keywords: COVID-19; Nirmatrelvir; Paxlovid; Rebound; Recurrence; Ritonavir.

PubMed Disclaimer

Comment in

References

    1. Hammond J., Leister-Tebbe H., Gardner A., Abreu P., Bao W., Wisemandle W., Baniecki M., Hendrick V.M., Damle B., Simón-Campos A., Pypstra R. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New Engl J Med. 2022;386(15):1397–1408. - PMC - PubMed
    1. K. Gupta, J. Strymish, G. Stack, M. Charness Rapid relapse of symptomatic omicron SARS CoV-2 infection following early suppression with nirmatrelvir/ritonavir. 26 April 2022, PREPRINT (Version 1) Accessed at Research Square doi:10.21203/rs.3.rs-1588371/v1. - DOI
    1. M. Charness, K. Gupta, G. Stack, J. Strymish, E. Adams, D. Lindy, H. Mohi, D. Ho. Rapid relapse of symptomatic omicron SARS CoV-2 infection following early suppression with nirmatrelvir/ritonavir. 13 May 2022, PREPRINT (Version 2). Accessed at Research Square doi:10.21203/rs.3.rs-1588371/v2. - DOI
    1. A.F. Carlin, A.E. Clark, A. Chaillon, A.F. Garretson, W. Bray, M. Porrachi, et al. Virologic and immunologic characterization of COVID-19 recrudescence after nirmatrelvir/ritonavir treatment. 18 May 2022, PREPRINT (Version 1). Accessed at Research Square doi:10.21203/rs.3.rs-1662783/v1. - DOI - PubMed
    1. COVID-19 rebound after paxlovid treatment. CDCHAN-00467. 24th May 2022. Accessed on 26th May 2022 at https://emergency.cdc.gov/han/2022/han00467.asp.